Open for Enrollment Soon

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Belvedere ML43000 (Neovascular Age-Related Macular Degeneration) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.

What is the Condition Being Studied?

Neovascular Age-Related Macular Degeneration (nAMD) AKA "Wet AMD"

Who Can Participate in the Study?

Adults ages 50+ who:

Are diagnosed with nAMD (within 18 months of joining study)
Have not received treatment with intravitreal corticosteroids
Have not had an intraocular surgery (including cataract surgery) within 6 months of joining the study

For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join the study, you will:

Get an eye implant, filled with ranibizumab
Be enrolled in the study for about 1 year
Visit our clinic at the Duke Eye Center up to 13 times during the study

At various visits, you will have blood tests, eye exams, and vision tests.

Study Details

Full Title

A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients with Neovascular Age-related Macular Degeneration Treated with the Port Delivery System with Ranibizumab (PDS) – Belvedere ML43000

Principal Investigator